Well, you say..."The issue would be whether the FDA would require a further larger study using Crestor/Apabetalone alone to replicate results."(assuming you mean for MACE)

So if we end up there would it not be more beneficial seeing that the combination of the two molecules saw a PAV plague regression of (-1.4%)  in ASSURE well over the pre-specified endpoint of (-0.6%).  Won't we end up with a drug for plaque regression and MACE?

Koo